Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir/Emtricitabine for COVID-19 Prevention in Healthcare Workers
NCT04519125Phase 3Unknown
- Sponsor
- Hospital Universitario San Ignacio
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing TDF/FTC + PPE with Placebo + PPE (2 arms). Primary endpoint: Incidence of SARS-CoV-2 infection at 75 days. Status: unknown.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04519125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519125.